Gilead Sciences, Inc. held its Annual Meeting of Stockholders on May 7, 2025. The meeting, which saw a significant quorum representing 1,121,336,290 shares of the 1,246,634,469 shares entitled to vote (approximately 90%), included critical votes on director elections, auditor ratification, executive compensation, and shareholder proposals.
Key Results from the Vote: - Nine directors were elected for the next year with robust support; vote totals ranged from approximately 981 million to 1 billion affirmative votes. - Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2025, with approximately 93% of votes in favor. - The advisory vote on executive compensation was approved with about 91% support. - Notably, several shareholder proposals were not approved, including those related to CEO pay ratio, independent Board Chair policy, human rights policy, and diversity and equity risk disclosures.
These voting outcomes reflect active governance engagement and shareholder perspectives on executive pay and corporate policies.
Financial Perspective: For context, Gilead Sciences reported total revenues of \(28.75 billion and net income of \)480 million for fiscal year 2024 (fiscal year ending December 31, 2024). These figures place into perspective the company’s ongoing scale and profitability as it navigates strategic and governance matters.
Recent Business Developments: Earlier in 2025, Gilead highlighted advances in its next-generation immuno-oncology products, including the KITE-363 bispecific CAR T for lymphomas and a bicistronic CAR T therapy for glioblastoma in collaboration with the University of Pennsylvania, signaling a pipeline focused on innovation with potential clinical impact.
Investment analysts watching Gilead should note the combination of strong shareholder governance engagement, ongoing clinical advancement, and financial baseline as imperatives for evaluating the company’s trajectory.
For detailed information and official disclosures, please refer to the original SEC filing: Source Document
Tags: GileadSciencesStockholderVote2025, ImmunoOncologyPipeline, CorporateGovernanceGilead2025, FiscalYear2024Results, CAR-TInnovations2025